These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Therapeutic applications of antisense DNA in the treatment of human leukemia. Gewirtz AM Ann N Y Acad Sci; 1992 Oct; 660():178-87. PubMed ID: 1285070 [No Abstract] [Full Text] [Related]
25. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625 [TBL] [Abstract][Full Text] [Related]
26. Antisense anticancer oligonucleotide therapeutics. Wang H; Prasad G; Buolamwini JK; Zhang R Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878 [TBL] [Abstract][Full Text] [Related]
27. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells. Rowley PT; Kosciolek BA; Kool ET Mol Med; 1999 Oct; 5(10):693-700. PubMed ID: 10602778 [TBL] [Abstract][Full Text] [Related]
28. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
29. Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia? Kronenwett R; Haas R Recent Results Cancer Res; 1998; 144():127-38. PubMed ID: 9304714 [No Abstract] [Full Text] [Related]
30. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise? de Fabritiis P; Calabretta B Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496 [No Abstract] [Full Text] [Related]
31. Chronic myelogenous leukemia: molecular and cellular aspects. Pasternak G; Hochhaus A; Schultheis B; Hehlmann R J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825 [TBL] [Abstract][Full Text] [Related]
32. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. de Fabritiis P; Amadori S; Calabretta B; Mandelli F Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986 [TBL] [Abstract][Full Text] [Related]
33. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study. Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842 [TBL] [Abstract][Full Text] [Related]
34. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Fernandes RS; Gorman AM; McGahon A; Lawlor M; McCann S; Cotter TG Leukemia; 1996 Jun; 10 Suppl 2():s17-21. PubMed ID: 8649049 [TBL] [Abstract][Full Text] [Related]
36. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654 [TBL] [Abstract][Full Text] [Related]
37. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells. Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445 [TBL] [Abstract][Full Text] [Related]
38. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009 [TBL] [Abstract][Full Text] [Related]
39. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Chasty R; Whetton A; Lucas G Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978 [TBL] [Abstract][Full Text] [Related]